Epidemiology of Atopic Dermatitis (AD) in Children Aged 6–11 Years: A Cross-Sectional Study in the United States (US), Canada, Europe, and Japan

Jonathan I. Silverberg,1 Sebastien Barbarot,2 Abhijit Gadkari,3 Eric L. Simpson,4 Stephan Weidinger,5 Paola Mina-Osorio,6 Lysel Briglini,6 Grece Saba,6 Miriam C. Fenton,7 Laurent Eckert8

1Department of Dermatology, The George Washington School of Medicine and Health Sciences, Washington, DC, USA; 2Department of Dermatology, Nantes University Hospital, Nantes, France; 3Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA; 4Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA; 5Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 6Kantar Health Division, Paris, France; 7Sanofi, Cambridge, Massachusetts, USA; 8Sanofi, Lyon, France; 8Sanofi, Chilly-Mazarin, France

BACKGROUND
• Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense pruritus and eczematous lesions, symptoms that are driven by T helper 2 (Th2)-mediated skin inflammation.1,2
• The symptoms of AD present persistently or as a fluctuating course of flares in between spontaneous apparent remission3,4 and cause significant burden, especially in those with moderate-to-severe disease.5,6
• AD typically appears in infancy or childhood, and in approximately 50% of cases, AD can extend into a chronic lifelong condition.7
• Moderate AD has been reported in 20–37% of adult patients and severe AD in 10–34%,8 however, currently, there are limited data on severity strata in children.

OBJECTIVE
• This study aimed to estimate the prevalence and severity of AD in children 6–11 years of age in the United States (US), Canada, Europe (EUS: France, Germany, Italy, Spain, the United Kingdom [UK]), and Japan.

METHODS
A cross-sectional, web-based, parent-report survey was administered in the US, Canada, Germany, France, Italy, Spain, the UK, and Japan.
• The study was conducted in accordance with the British Healthcare Business Intelligence Association’s European Pharmaceutical Market Research Association, Marketing Research Association, and additional local country codes of conduct, as well as data protection legislation.
• In each country, members of online consumer panels (Lightspeed Health, all countries; Research Now/SSI, all countries; Toluna, all countries except Japan; AIP, Japan) who met the inclusion criteria (parents/guardians of children aged 6–11 years) received an e-mail invitation to participate in the study.
• Each panel was responsible for sending the e-mail invitation to panel members; the e-mail invitations were consistent among each panel and did not mention skin disease or AD.
• Members of online panels were recruited through broad-reach portals, special interest sites, and direct e-mailing campaigns that were not specifically related to AD.
• All members:
  • agreed to be part of the online panel and their e-mail address was confirmed through a double-opt-in registration process
  • registered with demographic information, passed quality checkpoints, and agreed to country-specific terms and conditions and privacy policies.
• The parent/guardian provided consent and participated in a 30-min online survey.
• Patients (ie, the children) were not required to respond to any items of the survey related to prevalence and severity, but rather all were answered by the parent/guardian.
• Quintiles was set for respondents in specific categories relating to age and sex,9,10 and residence (urban/suburban/rural).11,12
• When quota objectives were not met, a weighting adjustment was applied to obtain a representative population with respect to sociodemographic characteristics for each country.
• Prevalence of AD was estimated using responses to survey questions based on the International Study of Atopy and Allergies in Childhood (ISAAC) criteria and self-reported physician diagnosis (Figure 1). Children were categorized as having AD if they met the ISAAC criteria and self-reported ever being told that a physician told them they had eczema.

RESULTS
• The samples were representative of the general population in each country with respect to age, gender, and urban/rural split (Table 1).
• One-year diagnosed AD prevalence estimates were: US, 10.0%; Canada, 13.3%; EUS, 15.5%; Japan, 10.3%; and all countries, 12.2% (Figure 2).
• Across countries, 84.4–91.0% of children with diagnosed AD were treated with prescription medication in the past 12 months (data not shown).
• Of these treated children, 43.6–60.1%, 35.0–45.4%, and 3.5–13.0% were categorized as having mild, moderate, and severe AD, respectively, based on POEM (Figure 3).
• Based on the PGA, 61.5–73.2%, 24.5–34.6%, and 2.3–8.4% of treated children were categorized as having mild, moderate, and severe AD, respectively (Figure 4).

CONCLUSION
• This international study of the prevalence of childhood AD in children 6–11 years of age estimated that prevalence of AD varied from 10.0% in the US to 15.5% in the EU 5 region.
• Severe AD by POEM and PGA varied in children treated with prescription medication, from 3.5% (on POEM) and 2.3% (on PGA) in Japan to 13.0% (on POEM) in the US and 8.4% in Canada (on PGA).
• Strengths of this study included its inclusion of ISAAC criteria for identifying AD, which enabled a consistent method of evaluating prevalence across countries, large sample sizes, and selection of subjects that provided broad representation of the populations and regions of each country.
• Limitations included observed variability, which may be due to misclassification, especially as outcomes were based on self-report by parents; each self-report additionally may have introduced the potential for recall bias. The online survey may also represent a form of selection bias, as this method of data collection presupposes computer literacy and internet access.

Table 1. Baseline demographics for survey respondents (country, n)

<table>
<thead>
<tr>
<th>Residence</th>
<th>US</th>
<th>Canada</th>
<th>EUS</th>
<th>Japan</th>
<th>All countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban</td>
<td>53</td>
<td>58</td>
<td>56</td>
<td>57</td>
<td>55</td>
</tr>
<tr>
<td>Suburban</td>
<td>47</td>
<td>42</td>
<td>44</td>
<td>43</td>
<td>45</td>
</tr>
<tr>
<td>Rural</td>
<td>48</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
</tr>
</tbody>
</table>

Figure 1. Assessment of the prevalence of AD

Figure 2. Prevalence of AD in children aged 6–11 years

Figure 3. Disease severity based on POEM among treated children aged 6–11 years with AD

Figure 4. Disease severity based on PGA among treated children aged 6–11 years with AD

CONCLUSION

• This international study of the prevalence of childhood AD in children 6–11 years of age estimated that prevalence of AD varied from 10.0% in the US to 15.5% in the EU 5 region.
• Severe AD by POEM and PGA varied in children treated with prescription medication, from 3.5% (on POEM) and 2.3% (on PGA) in Japan to 13.0% (on POEM) in the US and 8.4% in Canada (on PGA).
• Strengths of this study included its inclusion of ISAAC criteria for identifying AD, which enabled a consistent method of evaluating prevalence across countries, large sample sizes, and selection of subjects that provided broad representation of the populations and regions of each country.
• Limitations included observed variability, which may be due to misclassification, especially as outcomes were based on self-report by parents; each self-report additionally may have introduced the potential for recall bias. The online survey may also represent a form of selection bias, as this method of data collection presupposes computer literacy and internet access.